RANI Strangle Strategy

RANI (Rani Therapeutics Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

RANI (Rani Therapeutics Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $68.6M, a beta of 0.76 versus the broader market, a 52-week range of 0.387-3.87, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 105 full-time employees. These structural characteristics shape how RANI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.76 places RANI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on RANI?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current RANI snapshot

As of May 15, 2026, spot at $1.10, ATM IV 203.00%, IV rank 42.74%, expected move 58.20%. The strangle on RANI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on RANI specifically: RANI IV at 203.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 58.20% (roughly $0.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RANI expiries trade a higher absolute premium for lower per-day decay. Position sizing on RANI should anchor to the underlying notional of $1.10 per share and to the trader's directional view on RANI stock.

RANI strangle setup

The RANI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RANI near $1.10, the first option leg uses a $1.16 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RANI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RANI shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$1.16	N/A
Buy 1	Put	$1.05	N/A

RANI strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

RANI strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on RANI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on RANI

Strangles on RANI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RANI chain.

RANI thesis for this strangle

The market-implied 1-standard-deviation range for RANI extends from approximately $0.46 on the downside to $1.74 on the upside. A RANI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RANI IV rank near 42.74% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on RANI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RANI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RANI-specific events.

RANI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RANI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RANI alongside the broader basket even when RANI-specific fundamentals are unchanged. Always rebuild the position from current RANI chain quotes before placing a trade.

Frequently asked questions

What is a strangle on RANI?: A strangle on RANI is the strangle strategy applied to RANI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RANI stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed RANI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RANI strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RANI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 203.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RANI strangle?: The breakeven for the RANI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RANI market-implied 1-standard-deviation expected move is approximately 58.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on RANI?: Strangles on RANI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RANI chain.
How does current RANI implied volatility affect this strangle?: RANI ATM IV is at 203.00% with IV rank near 42.74%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.